✦ LIBER ✦

Phase II study of Docetaxel and Cisplatin in a circadian timing as first line chemotherapy (CT) in advanced non small cell lung cancer (NSCLC)

✍ Scribed by Faderl, B.; von Pawel, J.; Wagner, H.; Krauss, C.; Achterrath, W.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II study of Docetaxel and Cisplati

✍ Pawel, J.v.; Faderl, B.; Wagner, H.; Krauβ, C.; Achterrath, W. 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 90 KB

Phase III trial of docetaxel (D) and car

✍ Giannakakis, Th; Mavroudis, D; Papadouris, S; Kourousis, Ch; Ziras, N; Kakolyris 📂 Article 📅 1998 🏛 Elsevier Science 🌐 English ⚖ 224 KB

Docetaxel plus cisplatin as neoadjuvant

✍ Dediu, M; Horvat, T; Tarlea, A; Nicodin, A; Movanu, M; Radult, M 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 114 KB

Phase I study of docetaxel in combinatio

✍ Bildat, S.; Gatzemeier, U.; Reck, M.; Harstrick, A.; Eberhardt, W.; Achterrath, 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 158 KB

Gemcitabine plus docetaxel as first-line

✍ Joaquín Casal; Margarita Amenedo; José Ramón Mel; Luis Miguel Antón; Rubén Rodrí 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 343 KB

Phase II study of Gemcitabine, Ifosfamid

✍ Castellano, D; Lianes, P; Arcediano, A; Gómez-Martin, C; Ciruelos, E; Bezares, S 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 106 KB